SCHEMBL23988910

SCHEMBL23988910

Cc1cc(-c2cnn3cc(N4CC(C)C4)cnc23)c2cc(F)cc(F)c2n1

nearest known ligand 0.75

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ ACVR1 Q04771 20/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23988746 0.88 ACVR1 (0.76) ACVR1
SCHEMBL23989004 0.86 ACVR1 (0.76) ACVR1
SCHEMBL22075378 0.86 ACVR1 (1.00) ACVR1
SCHEMBL23988844 0.85 ACVR1 (0.69) ACVR1
SCHEMBL23988795 0.83 ACVR1 (0.76) ACVR1
SCHEMBL23988792 0.82 ACVR1 (0.61) ACVR1
SCHEMBL22074627 0.82 ACVR1 (1.00) ACVR1
SCHEMBL23988749 0.80 ACVR1 (0.76) ACVR1
SCHEMBL25607058 0.79 ACVR1 (0.87) ACVR1
SCHEMBL22075500 0.76 ACVR1 (1.00) ACVR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021222875-A1 METHODS OF USING ALK2 INHIBITORS KEROS THERAPEUTICS, INC. (US) 2021-11-04 — — WO disclosed
Send feedback